Marit Muri Holmen
A5065456551- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Genetic Associations and Epidemiology
- Genomic variations and chromosomal abnormalities
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
- AI in cancer detection
- Digital Radiography and Breast Imaging
- Advanced Biosensing Techniques and Applications
- Cancer-related molecular mechanisms research
- Molecular Biology Techniques and Applications
- Nutrition, Genetics, and Disease
- Advanced Breast Cancer Therapies
- Ovarian cancer diagnosis and treatment
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Single-cell and spatial transcriptomics
- RNA modifications and cancer
Oslo University Hospital
2013-2022
University of Oslo
2021
Norwegian Cancer Society
2004
To explore the predictive value of MRI parameters and tumour characteristics before neoadjuvant chemotherapy (NAC) to compare changes in size apparent diffusion coefficient (ADC) during treatment, between patients who achieved pathological complete response (pCR) those did not. Approval by Regional Ethics Committee written informed consent were obtained. Thirty-one with invasive breast carcinoma scheduled for NAC enrolled (mean age, 50.7; range, 37–72). Study design included treatment (Tp0),...
The addition of annual MRI screening to mammography has heightened optimism that intensive along with improved treatments may substantially improve life expectancy women at high risk breast cancer. However, survival data from BRCA2 mutation carriers undergoing combined are scarce. We have collated the results either or in female Manchester and Oslo use a control group who had their first cancer diagnosed without screening. Eighty-seven undergone (n = 34) 53) compared 274 such Ten year...
Abstract Background Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants differential associations by estrogen receptor (ER) status, but how relate with other tumor features and intrinsic molecular subtypes is unclear. Methods Among 106,571 invasive cases 95,762 controls European ancestry data on 173 in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate relation (ER,...
Purpose: Chemotherapy-induced alterations to gene expression are due transcriptional reprogramming of tumor cells or subclonal adaptations treatment. The effect on whole-transcriptome mRNA was investigated in a randomized phase II clinical trial assess the neoadjuvant chemotherapy with addition bevacizumab.Experimental Design: Tumor biopsies and profiles were obtained at three fixed time points 66 patients each arm. Altogether, 358 specimens from 132 available, representing state before...
Mammographic density (MD), as assessed from film screen mammograms, is determined by the relative content of adipose, connective and epithelial tissue in female breast. In epidemiological studies, a high percentage MD confers four to six fold risk elevation developing breast cancer, even after adjustment for other known cancer factors. However, biologic correlates are little known. Gene expression analysis using whole genome arrays was performed on biopsies 143 women; 79 women with no...
Abstract Background Increased understanding of the variability in normal breast biology will enable us to identify mechanisms cancer initiation and origin different subtypes, better predict risk. Methods Gene expression patterns biopsies from 79 healthy women referred diagnostic centers Norway were explored by unsupervised hierarchical clustering supervised analyses, such as gene set enrichment analysis ontology comparison with previously published genelists independent datasets. Results...
Although systemic immunity is critical to the process of tumor rejection, cancer research has largely focused on immune cells in microenvironment. To understand molecular changes patient response (SR) presence BC, we profiled RNA blood and matched from 173 patients. We designed a system (MIxT, Matched Interactions Across Tissues) systematically explore link processes expressed each tissue. MIxT confirmed that active SR are especially relevant BC immunogenicity. The nature interactions across...
Tumor-host interactions extend beyond the local microenvironment and cancer development largely depends on ability of malignant cells to hijack exploit normal physiological processes host. Here, we established that many genes within peripheral blood show differential expression when an untreated breast (BC) is present, harnessed this fact construct a 50-gene signature distinguish BC patients from population-based controls. Our results were derived series large datasets our unique Norwegian...
Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) inhibits its receptor interaction, thus obstructing formation of new blood vessels. phase II randomized clinical trial 123 patients with Her2-negative breast cancer was conducted, treated chemotherapy (fluorouracil (5FU)/epirubicin/cyclophosphamide (FEC) taxane), or without bevacizumab. Serial biopsies...
Abstract Background Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, it is still equivocal whether causally related to risk. Methods We applied Mendelian randomisation (MR) evaluate potential causal effect of cigarette on Both individual-level data as well summary statistics for 164 single-nucleotide polymorphisms (SNPs) in genome-wide studies lifetime index (LSI) or per day (CPD) were used obtain MR estimates. Data from...
Abstract Background Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of cancer patients. Methods We performed genome-wide association analyses 15 patients based on prognostic factors, including hormone receptors, tumor grade, age, type systemic treatment. Analyses were 91,686 female European ancestry from Breast Cancer Association Consortium,...
We report prospectively observed risk for breast cancer in kindreds without a demonstrable BRCA1/2 mutation. According to family history, the optimal available member(s) of each kindred attending our clinic was tested BRCA mutations. Women families mutation were subjected annual mammography. mutations demonstrated 496/2,118 (23 %) kindreds. In mutation, total 3,161 healthy women aged 25-59 years followed 24,808 observation years. Sixty-four cancers observed, compared 34.0 expected (p <...
Abstract BACKGROUND: In this phase II clinical trial, patients with HER2 negative primary tumors of ≥25 mm were treated neoadjuvant chemotherapy (4 x FEC100 + 12 weeks taxane-based therapy) and randomized (1:1) to receive bevacizumab or no bevacizumab. Mammography, ultrasound MR imaging used for response evaluation, in addition final pathology assessment. HYPOTHESIS: RPPA proteomic analyses support identification molecular mechanisms associated treatment. METHODS: Tumor responses evaluable...
Abstract NBS1, also known as NBN, plays an important role in maintaining genomic stability. Interestingly, rs2735383 G > C, located a microRNA binding site the 3′-untranslated region (UTR) of NBS1 , was shown to be associated with increased susceptibility lung and colorectal cancer. However, relation between breast cancer is not yet clear. Therefore, we genotyped 1,170 familial non- BRCA1/2 cases 1,077 controls using PCR-based restriction fragment length polymorphism (RFLP-PCR) analysis,...
Abstract In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression ER-positive cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate risk allele, we evaluated the association between germline mutations in previous study consisting 3,270 familial non- BRCA1/2 cases 2,327 controls from Netherlands. Although both recurrent p.R217C were not risk, estimation for was very precise. To provide more conclusive...
High mammographic density (MD) is associated with a 4–6 times increase in breast cancer risk. For post-menopausal women, MD often decreases over time, but little known about the underlying biological mechanisms. reflects tissue composition, and may be microenvironment subtypes previously identified tumor-adjacent normal tissue. Currently, these have not been explored We obtained biopsies from breasts of healthy women at two different time points several years apart performed microarray gene...
Abstract The NeoAva study is a phase II clinical trial of patients with HER2 negative primary tumors ≥25 mm treated neoadjuvant chemotherapy (4 x FEC100 + 12 weeks taxane-based therapy) and randomized (1:1) to receive bevacizumab or no bevacizumab. Mammography, ultrasound MR imaging were used for response evaluation, in addition final pathology assessment. Tumor evaluable 131 patients; which 66 received chemotherapy. material was obtained at screening, into treatment surgical removal 25...
2523 Background: The molecular characteristics of responding and non-responding breast cancers when treated with antiangiogenic therapy are largely unknown. Methods: To investigate alterations in tumors therapy, the NeoAva study included patients HER2 negative primary ≥ 25 mm that were randomized (1:1) to receive chemotherapy (4 x FEC100 + 12 weeks taxane-based therapy) or without bevacizumab. Tumor material was obtained at screening, into treatment surgical removal weeks. mRNA expression...
Mammographic features of calcifications on mammograms showing invasive breast cancer are associated with survival. Less is known about mammographic and progression to among women treated for ductal carcinoma in situ (DCIS).To investigate screen-detected DCIS who later did not get diagnosed cancer.This registry-based nested case-control study analyzed data from BreastScreen Norway, 1995-2016. Within this cohort DCIS, those were (cases) matched (1:2) (controls) after their by the end 2016....